At a glance
A combined research record involving the component peptides and proportions documented for Tri-Heal.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together the component peptides and proportions documented for Tri-Heal. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][4][5]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][4][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tri-Heal.
Source-reported adverse effects and cautions
Note: Human clinical data on this specific combination is limited; observations are extrapolated from studies of individual components.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 45 mg · 3 source tables
Standard 8-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
*Precision Note: For doses ≤10 units (≤0.10 mL), consider using 30-unit or 50-unit insulin syringes for improved readability and accuracy. Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to optimize syringe accuracy across all dose levels.
Extended 12-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
Extended 16-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | 0.5 mg | 3.3 units* | 0.033 mL |
| Weeks 3–4 | 1000 mcg | 1.0 mg | 6.7 units* | 0.067 mL |
| Weeks 5–6 | 1500 mcg | 1.5 mg | 10 units | 0.10 mL |
| Weeks 7–8 | 2000 mcg | 2.0 mg | 13.3 units | 0.133 mL |
| Weeks 9–10 | 2500 mcg | 2.5 mg | 16.7 units | 0.167 mL |
| Weeks 11–12 | 3000 mcg | 3.0 mg | 20 units | 0.20 mL |
| Weeks 13–14 | 3500 mcg | 3.5 mg | 23.3 units | 0.233 mL |
| Weeks 15–16 | 4000 mcg | 4.0 mg | 26.7 units | 0.267 mL |
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support tissue repair, regeneration, and inflammation modulation through synergistic peptide action[1][2][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500–4000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 45 mg vial (15 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Suggested daily titration approach.
- Start: 500 mcg daily; increase by 500 mcg every 2 weeks as tolerated.
- Target: 1500–2000 mcg daily by Weeks 5–8 (standard); up to 3000–4000 mcg for extended protocols.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites systematically.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the lyophilized cake.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with date and concentration (15 mg/mL); refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) or colder (ideally −80 °C / −112 °F for long-term) in dry, dark conditions[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks; prepare aliquots if needed and avoid freeze–thaw cycles[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry completely before proceeding.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[8].
- Dispose of used syringes in an approved sharps container; never recap or reuse needles.
Materials & quantity planning
Source materials checklist · 45 mg
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (Tri-Heal, 45 mg each):
- 8 weeks (56 doses, ~70 mg total): 2 vials
- 12 weeks (84 doses, ~147 mg total): 4 vials
- 16 weeks (112 doses, ~252 mg total): 6 vials
- Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Recommendation: Include 30-unit or 50-unit syringes for the early low-dose phases (Weeks 1–4) where precision is critical.
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 45 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Public health resource
HSS Journal / PMC (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Frontiers in Endocrinology (2021) — Progress on the Function and Application of Thymosin β4 (opens in a new tab)www.frontiersin.org
Back to overview ↑ - 05
Research publication
Current Reviews in Musculoskeletal Medicine (2025) — Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
- 08
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review / PMC — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.